In response: Niacin-induced hepatotoxicity is dose-related and occurs with both immediate-release and sustained-release formulations. Our retrospective cohort study (1) did not include patients receiving immediate-release niacin, and some cases of elevated hepatic enzyme levels may have been missed. In a prospective study, Lavie and colleagues (2) treated patients with "isolated" low high-density lipoprotein cholesterol levels using a sustained-release niacin preparation similar to the one we used. At a mean daily niacin dose of 2400 mg, 3% of their 36 patients were withdrawn from the study because of threefold elevations in aminotransferase values. Hepatic dysfunction was found in fewer than 3% of nearly 300 other patients (2). Thus, it is unlikely that we missed a significant number of patients with hepatic dysfunction because of the retrospective nature of our study.
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Pharmacoepidemiology of Niacin
To the Editor: We feel that Gray and colleagues' data (1) do not support their claim that controlled-release and immediaterelease niacin have similar toxic effects when used in equipotent doses. Because their study did not include a control group, it did not provide a basis for evaluating differences between the controlled-release and immediate-release forms. The study design probably also resulted in an underestimation of the incidence of niacin-associated hepatotoxicity (the most serious niacin toxicity). Hepatotoxicity was identified by notations on the medical record or by evidence of elevated alkaline phosphatase or aminotransferase levels. However, the authors did not report the frequency of either clinic visits or laboratory monitoring. If visits or monitoring occurred infrequently, asymptomatic elevations of hepatic enzyme levels or hepatotoxicity presenting as a mild flu-like illness could have been missed.
In contrast, the clinical trial of McKenney and colleagues (2) was designed to evaluate differences between sustained-release and immediate-release niacin across varying doses. With sustained-release niacin, they found significant increases in aspartate aminotransferase and alanine aminotransferase levels at doses of 1500 mg/d or greater; with immediate-release niacin, no such increases were seen at doses as high as 3000 mg/d. Moreover, therapy had to be discontinued because of elevated liver enzyme levels in 12 of 23 patients receiving sustained-release niacin but in no patients receiving immediate-release niacin. Therapy with sustained-release niacin was discontinued at a dose of 1000 mg/d in one patient and at 1500 mg/d in two patients. These findings suggest that sustained-release niacin is more hepatotoxic than immediate-release niacin, even when administered at half the dosage, and argue against Gray and colleagues' claim of similar toxicity at equipotent doses.
The data of McKenney and associates (2) and numerous case reports (3, 4) continue to support the greater hepatotoxic potential of controlled-release niacin preparations and the use of immediate-release niacin as the preferred preparation.
In response: Niacin-induced hepatotoxicity is dose-related and occurs with both immediate-release and sustained-release formulations. Our retrospective cohort study (1) did not include patients receiving immediate-release niacin, and some cases of elevated hepatic enzyme levels may have been missed. In a prospective study, Lavie and colleagues (2) treated patients with "isolated" low high-density lipoprotein cholesterol levels using a sustained-release niacin preparation similar to the one we used. At a mean daily niacin dose of 2400 mg, 3% of their 36 patients were withdrawn from the study because of threefold elevations in aminotransferase values. Hepatic dysfunction was found in fewer than 3% of nearly 300 other patients (2) . Thus, it is unlikely that we missed a significant number of patients with hepatic dysfunction because of the retrospective nature of our study.
We could identify several factors (hypoglycemic agents, alcohol abuse, and niacin dose) that may predispose patients to niacininduced hepatotoxicity. By avoiding the use of controlled-release niacin in patients at risk and by treating selected patients with a dose of 1.0 to 2.0 g/d, we have found that controlled-release niacin yields favorable results in terms of tolerance, safety, and efficacy. Both immediate-release and sustained-release niacin were poorly tolerated in the study by McKenney and colleagues (3), which included fewer patients and had withdrawal rates of 39% (9 of 23 patients) and 78% (18 of 23 patients), respectively. Hepatotoxicity, which did not occur in the immediate-release niacin group, was frequent in the sustained-release group, occurring primarily at doses of 2 g/d or higher in 9 of 12 patients. Timed-release niacin capsules, the formulation of sustained-release niacin used by McKenney and colleagues, may not be bioequivalent to other sustained-release niacin formulations (4) and may also be associated with greater hepatoxicity.
Niacin is a broad-spectrum lipid-lowering agent with favorable effects on low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride levels. As indicated in the National Cholesterol Education Program guidelines (5), niacin can be safely and effectively prescribed with proper patient selection, dosing, and monitoring. Not all niacin formulations are the same. Significant differences in safety and efficacy can exist among different sustained-release preparations of niacin, many of which are available without medical supervision. This issue needs to be explored further, and a regulatory policy should be developed for use of niacin in the management of Dislipoproteinemia.
Hyperthyroidism
To the Editor: A review article on hyperthyroid disease (1) described immune-mediated leukopenia associated with Graves disease. I describe a patient with thrombocytopenia that complicated Graves disease.
A 24-year-old pregnant Hispanic woman had Graves disease at 14 weeks gestation and was treated with propylthiouracil. Three weeks later, a routine complete blood count showed a platelet count of 20 000 cells/mm 3 . Examination of a bone marrow biopsy specimen showed increased megakaryocytes, and platelet-associated IgG and IgM antibodies were elevated. She was treated successfully with prednisone, 100 mg daily.
In one series (2), five patients with Graves disease and thrombocytopenia were described. As was the case with our patient, two patients had idiopathic thrombocytopenic purpura-like illnesses that responded to prednisone. Four of the five patients were Latin American, which raises the interesting possibility of a heritable component in Hispanic patients.
Autoimmunity is one mechanism to explain the thrombocytopenia sometimes seen in hyperthyroid states, and it may be responsible for the extremely low platelet counts seen in patients with idiopathic thrombocytopenic purpura-like illnesses (2) . The underlying derangement in immune function that results in autoantibody formation may lead separately to the production of antithyroid and antiplatelet antibodies. Cross-reaction between antithyroid antibodies and the thyrotropin receptors on leukocytes has been postulated to account for the leukopenia sometimes seen in Graves disease, although no similar mechanism has been proposed for platelet destruction.
Increased activation of the reticuloendothelial system in hyperthyroid states is found in humans and in animal models, and this mechanism may account for the more mild cases of thrombocytopenia that are seen with hyperthyroidism. Platelet survival curves were shortened in all patients with hyperthyroidism whom we studied (3), and 43% of patients with untreated hyperthyroidism were frankly thrombocytopenic (4). Conversely, 14% of patients with unexplained thrombocytopenia had hyperthyroidism (5) .
Clinicians need to be alert for thrombocytopenia that complicates Graves disease. Recommendations to check thyroid function in patients with unexplained thrombocytopenia (2) seem appropriate.
Brian J. Bohlmann, MD
Madison, WI 53717-1081 cytopenic purpura and hyperthyroidism. Ann Intern Med. 1967;67: 411-4.
To the Editor:
The review by Klein and colleagues (1) on the treatment of hyperthyroid disease was comprehensive and well balanced. However, several important issues were not fully covered. I concur that propylthiouracil is the preferred therapy in pregnant women, not only because of the low or nonexistent risk for teratogenicity but also because of the rare abnormality of aplasia cutis congenita that may be associated with the use of methimazole in pregnancy.
Two distinct antithyroid drug regimens are available. In the first, the dose of drug is titrated to keep the patient euthyroid; in the second, a fixed drug dose is used to block thyroid hormone production, and iatrogenic hypothyroidism is averted by thyroxine replacement (block-replace). The block-replace regimen is easier to use; involves fewer clinic visits to achieve euthyroidism; and, theoretically, because a larger total dose of methimazole is being given, greater immunosuppressive effects on thyroid receptor antibody levels may occur. When the block-replace regimen is used for 6 months, remission rates of 59% can be achieved at 1 year (2). If symptoms do recur after this short course, definitive treatment with radioiodine or surgery can be offered sooner than when the standard titration regimens lasting 1 to 2 years are used.
Regarding their discussion of the treatment of thyroid-stimulating hormone-secreting pituitary adenomas, I agree that surgery is the cornerstone of therapy. However, adjunctive pituitary radiotherapy and the use of somatostatin analogs were not described. Many of these tumors tend to be large and invasive. In most cases, surgical removal is incomplete, and, even after pituitary irradiation, only about 40% of patients can be cured. In a review of 52 patients with thyroid-stimulating hormone-secreting adenomas, octreotide (a long-acting somatostatin analog) was found to reduce thyroid hormone levels in all patients, and these levels returned to normal in 77% of patients (3). Partial tumor shrinkage was observed in one third of patients receiving longterm octreotide therapy. Octreotide is an effective treatment when surgery and radiotherapy have failed to cure the disease, and it requires further evaluation as a primary treatment for these tumors.
Glenn Matfin, MBChB, DGM, MRCP J.A. Haley Veterans Hospital Tampa, FL 33612
To the Editor: I enjoyed the article by Klein and associates (1) on the management of hyperthyroidism. However, I was surprised by their statement that anticoagulation with warfarin is not routinely recommended to prevent arterial thromboembolism in patients with hyperthyroidism and atrial fibrillation who do not have organic heart disease (mitral valve disease) or congestive heart failure. This statement is not consistent with data that the reported frequency of arterial thromboembolism exceeds that of congestive heart failure or mitral valve disease in patients with hyperthyroidism (2-4). Given the devastating effect of arterial thromboembolism and the documented protective effects of anticoagulation, it seems prudent to routinely recommend warfarin treatment unless contraindications to its use exist. To the Editor: In their review, Klein and colleagues (1) state that radioiodine is the "preferred" treatment for Graves disease. Although this is the most frequently chosen form of therapy in the United States, antithyroid drug therapy is most often used in Europe and Japan (2) . Historical, social, and cultural factors underlie, in part, these geographic differences in choices of therapy. Arguments can be made for each form of therapy, but, given the differing practices around the world, radioactive iodine is "preferred" only because it is currently the therapy most widely used by U.S. physicians and not necessarily because it is the most desirable therapy for patient outcomes. In the study by Hashizume and colleagues (3), which dealt with only limited numbers, more than 95% of patients remained euthyroid 3 years after completion of therapy with methimazole plus thyroxine. As Klein and colleagues indicated, this striking result must be confirmed by others, preferably in different locations. Because Graves disease is common, studies must be done so physicians can choose therapy based not on popular preferences but on patient outcomes. Multicenter trials seem the most efficient way to establish "preferred" (that is, desirable) outcome-based therapies (4, 5) .
Gordon N. Gill, MD University of California, San Diego La Jolla, CA 92093-0650
In response: Dr. Bohlmann described a case of thrombocytopenia in a pregnant woman with Graves disease who was treated with propylthiouracil. Although the association of Graves disease and thrombocytopenia is well known, it is not clear from the case that the decrease in the platelet count was related to the propylthiouracil therapy or, alternatively, the manifestation of coexistent autoimmune thrombocytopenia. If treatment with propylthiouracil was continued, it would be interesting to know if the patient was still receiving propylthiouracil when she responded to prednisone. Propylthiouracil-mediated agranulocytosis is presumably immunologically mediated. A report from Magner and Snyder (1) provides additional evidence for the potential usefulness of human granulocyte-colony-stimulating factor in the treatment of propylthiouracil-induced agranulocytosis. As we suggested (2), stimulation of granulocyte stem cells may hasten recovery from this side effect of treatment.
As Dr. Matfin knows, page constraints limit the depth and breadth of the discussion, even in review articles. Our main focus was to describe the management of the common forms of hyperthyroidism. We agree that for the treatment of the rare pituitary adenoma causing hyperthyroidism, adjunctive therapy beyond surgery may be required. The comments about octreotide therapy are potentially useful and may apply to individual patients.
The management of patients with hyperthyroidism who have atrial fibrillation carries additional considerations. We disagree with Dr. Woeber and adhere to our recommendations (2) 
acute onset and will spontaneously revert to sinus rhythm without associated side effects (3); the prevalence of systemic embolization in patients with hyperthyroidism who have atrial fibrillation has not been sufficiently studied to identify the actual risk (4); and studies of groups larger than those in previous trials would indicate that the prevalence of systemic embolization is much lower than previously reported (Nakazawa H. Personal communication). In light of these considerations and in keeping with the conclusions reached by Presti and Hart (4), the decision to treat thyrotoxic patients with atrial fibrillation needs to be made on a case-by-case basis, addressing relevant variables such as advanced age, the presence of organic heart disease, and heart failure.
Dr. Gill questions our statement that radioiodine is the preferred treatment for patients with Graves disease. He suggests that a multicenter trial is necessary to arrive at such a conclusion. To the contrary, because radioiodine is the most frequently chosen form of treatment in the United States and because of its high likelihood of success and limited, if any, side effects, we find the term "preferable" appropriate. If other forms of therapy or modifications of existing treatments are developed in the future, their effectiveness must be compared with that of radioiodine treatment. Our opinion remains as stated. 
Irwin Klein, MD

Helicobacter pylori and Peptic Ulcer
To the Editor: We commend Nomura and coworkers (1) for using an existing cohort to increase our understanding of the relation between Helicobacter pylori and peptic ulcer disease. However, the nested case-control design that was used has a few methodologic problems. First, the case-control design was used in the context of a cohort design, and principles that apply to the cohort design should be respected. Specifically, the disease status (duodenal or gastric ulcer) at study entry is unknown. Consequently, the population at risk may not have been free of disease when the blood samples were collected. If persons in whom peptic ulcer disease develops are more likely to have a history of peptic ulcer disease, even if asymptomatic, they will be more likely to have antibodies to H. pylori when blood samples are measured at baseline. Therefore, the reported association will be overestimated. Second, the authors excluded the controls who developed peptic ulcer disease. In such a design, controls who develop disease should be included as case-patients. By excluding them, the reported association is again overestimated because several case-patients who probably did not have antibodies will not be counted. At the very least, the antibody status of these persons should be reported. Because of these methodologic issues, the reported positive association may be overestimated, and persons who develop peptic ulcer disease may not be more likely to have had previous high levels of antibodies to H. pylori. Nested case-control studies are an efficient way to answer questions of cause and effect from previously collected data. The many design issues should be handled with care to prevent erroneous conclusions.
Louise Pilote, MD, MPH Cleveland Clinic Foundation Cleveland, OH 44195
In response: We appreciate Dr. Pilote's concerns. First, the patients' disease status (duodenal or gastric ulcer) at entry in the cohort was known. As stated in the Methods section of our article, 481 patients (of a cohort of 5924 men) with previous gastrectomy or a previous diagnosis of peptic ulcer disease were excluded from the study. It is standard practice in a cohort study to exclude persons who, at baseline, have the disease being investigated. Consequently, study participants who were known to have peptic ulcer from their interview or from review of hospital records were not included in our study.
Second, it is not clear what Dr. Pilote means by the statement, "... the authors excluded the controls who developed peptic ulcer disease." From the remaining 5443 men in the study, 229 were hospitalized with peptic ulcer disease between 1968 and 1989. These 229 patients were the case-patients for this study, and 229 controls (matched by age at examination and by date of serum collection) were identified among the men who were not hospitalized with peptic ulcer disease. As a result, any patient hospitalized with peptic ulcer during the 21-year surveillance period was identified as a case-patient and was removed from the list of potential controls in the study.
We pointed out in our Discussion that we identified hospitalized patients with peptic ulcer, but, because of practical considerations, we could not identify nonhospitalized patients in whom peptic ulcer disease was diagnosed during the surveillance period. If nonhospitalized patients with peptic ulcer are included in the control group and if a positive association with H. pylori infection also exists among these patients with less complicated disease, the findings in our study underestimate the strength of the association between peptic ulcer disease and previous infection with H. pylori. 
Crohn Disease and the Myelodysplastic Syndrome
To the Editor: An association was suggested to exist between the myelodysplastic syndromes and Crohn disease on the basis of concomitant rinding of these disorders in a series of four patients (1) . Three of these patients had clonal abnormalities of chromosome 20 in the bone marrow cells. The potential role of immune dysfunction as a common pathogenetic factor of the myelodysplastic syndromes and inflammatory bowel disease was also discussed.
We describe a 70-year-old man with a 20-year history of irritable bowel disease who presented with signs of a hematologic disorder. Symptoms of irritable bowel disease were mild until October 1991, when the patient had frequent diarrhea. In July 1992, he presented with anemia (hemoglobin level, 6.7 g/dL), leukopenia (leukocyte count, 3.9 X 10 9 /L), and thrombocytopenia (platelet count, 117 X 10 9 /L). A bone marrow smear showed increased erythropoiesis with megaloblastic and dyserythropoietic characteristics and was consistent with a diagnosis of refractory anemia (myelodysplastic syndrome type 1) or, alternatively, reactive changes (2) 
with a diagnosis of Crohn disease. The leukocyte and platelet counts decreased to 1.1 X 10 9 /L and 13 x 10 9 /L, respectively. A second bone marrow smear showed 25% dysplastic erythropoiesis with 30% ringed sideroblasts. Twenty-five percent immature myeloid cells was present, compatible with a diagnosis of myelodysplastic syndrome type 5 (2) . Cytogenetic analysis of bone marrow cells showed no clonal abnormalities, but such findings are absent in about 50% of cases of the myelodysplastic syndrome (3). The patient died in February 1993.
The myelodysplastic syndromes are rare (4) and usually develop in patients older than age 60 years. Crohn disease is typically diagnosed in younger persons, with a suggested second peak after 60 years (5) . Although the association between the myelodysplastic syndrome and Crohn disease might be coincidental, further support of a potential susceptibility to the development of the syndrome in patients with Crohn disease should be systematically sought. Meanwhile, the possibility of the myelodysplastic syndrome should be considered in patients with Crohn disease who develop cytopenias.
Kirsten Muri Boberg, MD Lorentz Brinch, MD Morten Vatn, MD
Rikshospitalet 0027 Oslo, Norway
Castleman Disease and Renal Amyloidosis
To the Editor: Giant lymph node hyperplasia was initially described by Castleman and colleagues (1) in 1956 as a solitary mediastinal lesion. Since then, isolated cases of this rare disease have been reported in other sites (2) and have been described under two clinicopathologic variants: the hyaline vascular type and the plasma cell type. Systemic manifestations such as fever, anemia, increased erythrocyte sedimentation rate, and hypergammaglobulinemia frequently accompany the plasma cell variant and subside after the lesion is removed (3). We describe a patient successfully treated with surgery alone for Castleman disease associated with renal amyloidosis.
A 48-year-old woman who had had profound and chronic microcytic and hypochromic anemia since 1976 and who was unresponsive to iron therapy was hospitalized for a nephrotic syndrome. Results of a physical examination were normal. Laboratory findings were as follows: erythrocyte sedimentation rate, 105 mm/h; hemoglobin level, 5.3 g/dL; erythrocyte count, 3 X 10 12 /L; mean corpuscular volume, 63.5 /mm 3 ; reticulocyte count, 1%; platelet count, 626 000 cells/mm 3 ; serum iron concentration, 6 /Ltmol/L; and ferritin concentration, 402 /ig/L. Acute-phase protein levels were markedly elevated. The serum creatinine level was 197 /Ltmol/L; the serum albumin level was 24 g/L; and proteinuria was present at 18 g/d. Results of a bone marrow examination were normal. Examination of a kidney biopsy specimen showed amyloidosis of the AA type. The patient had no history of recurrent infections, chronic inflammatory diseases, autoimmune diseases, or neoplasms. No other specific diagnosis was made. A computed tomographic scan of the abdomen showed a partially calcified mesenteric mass that was lateral to the aorta and thought to represent lymphadenopathy.
Resection of the mass showed a localized plasma-cell variant typical of Castleman disease. Examination of a liver biopsy specimen showed amyloidosis, as did the stomach fibroscopy. One month after surgical resection, the patient's renal function considerably improved. Her serum creatinine level was 110 /imol/L, the nephrotic syndrome had disappeared, and her hemoglobin level was 9 g/dL. Three months later, her renal function was normal, her hemoglobin level was stable, and the acute phase reactant levels had decreased to normal values.
Castleman disease has been associated with renal amyloidosis in very few patients. Nevertheless, the disease should be suspected in all patients presenting with anemia, inflammatory syndromes, and amyloidosis of the AA type. In addition to surgical resection of the tumor, patients may have received such therapies as monoclonal anti-interleukin-6 antibody (BE-8) (4), corticosteroids, and high-dose dexamethasone and have had splenectomy.
In our patient, Castleman disease was associated with renal and extrarenal amyloidosis. The resection of the lymphomatic mass corrected most abnormalities, including the nephrotic syndrome and renal insufficiency. We suggest that surgery should be used in similar cases as the first-line treatment before administration of corticosteroids or any other potentially aggressive drug.
/. Kazes, MD G. Deray, MD C. Jacobs, MD Hopital Pitie-Salpetriere Paris, France
Transient Ischemic Attack after Air Contrast Echocardiography in Patients with Septal Aneurysm
To the Editor: Intravenous air is frequently used during echocardiography to show right-to-left heart shunting (1). Small amounts are considered safe because of the lung's filtering action. Associated cerebral ischemic symptoms have not been reported either because of their infrequency or subtlety or because of a reluctance to report an iatrogenic complication. We have done 46 air contrast studies in patients in whom atrial septal aneurysm was diagnosed during routine echocardiography. Rightto-left shunts were found in seven patients, and transient ischemic attacks occurred in three patients.
Contrast echocardiography (2) was done using 10 mL of agitated air and normal saline. No patient had a history of transient ischemic attack. In two patients, transcranial Doppler studies were done during or after the procedure. Air emboli were identified in both patients for as long as 2 hours by their characteristic audio "chirps" and transcranial Doppler waveform (3).
All symptoms appeared when patients arose, and they resolved in minutes or hours. Neurologic deficits consisted of dizziness and paraparesis with numbness in patients with large shunts; diplopia, left hemiparesis, and right seventh-nerve weakness in patients with moderate shunts; and left upper extremity numbness and paresthesias in patients with small shunts.
Air embolism appeared to be responsible for the observed symptoms because no patient had a history of transient ischemic attack and because symptoms occurred soon after procedures done with documented intracranial air emboli. Clinicians should exercise care when injecting air bubbles, given the risk for neurologic deficits. Vigorous agitation of the air contrast to reduce bubble size does not completely eliminate this risk. Use of a more soluble gas, such as oxygen or carbon dioxide, may be prudent. Further, because of the risk for paradoxical air embolism in patients with unsuspected right-to-left heart shunts, great care should be exercised in the flushing and proper connection of intravenous lines in all patients.
Nonsteroidal Anti-inflammatory Drugs and High Blood Pressure
To the Editor: I was surprised by the recent meta-analysis by Johnson and colleagues (1) on nonsteroidal anti-inflammatory drugs (NSAIDs) and blood pressure. Several important aspects of the validity and generalizability of the study need serious attention before readers can apply the information.
First, the "methodologic rigor" for individual studies was not very rigorous. For example, the study by Radack and colleagues (2) included 41 patients, not 30. The patients were predominantly black women (21 of 41 patients), not white (their Appendix  Table 1 ), and the male-to-female ratio was 15:26, not 7:19 (their Appendix Table 1 ). We highlighted these differences by discussing the potential effect on both the pharmacoepidemiology and generalizability of our findings. Second, in the first published methodologic review of NSAIDs and blood pressure control (3), my colleagues and I reached different conclusions on the quality of the clinical trials (those done before 1987). In fact, the methodologic heterogeneity was so great that we omitted a pooled summary estimate to avoid a meaningless conclusion. Third, Johnson and colleagues (1) reported their results as mean arterial pressure, a relatively useless outcome variable for the practicing clinician. Although all articles reviewed up to 1986 (and after) have reported both systolic and diastolic blood pressure values, the latter was omitted from Johnson and colleagues' meta-analysis. Given the well-established lack of consistent and quantitatively important changes in many of the laboratory measures reported in their meta-analysis, information on systolic and diastolic blood pressure would have been far more useful and clinically sensible to practitioners than some of the data provided in their Table 1 .
Finally, as an advocate and producer of meta-analyses, I strongly urge more careful and thoughtful assessment by reviewers and editors if the credibility of meta-analyses is to grow (4).
Ken Radack, MD, MS
University of Cincinnati Medical Center Cincinnati, OH 45267-0535
